Results 91 to 100 of about 10,710,575 (236)

CANCER OF THE BREAST

open access: yesSouthern Medical Journal, 1919
n ...
openaire   +1 more source

Breast Cancer Tissue Bank Search Tool

open access: yes
The Research Query page is a component of the Breast Cancer Tissue Bank website. It shows the numbers of consented patients, and the numbers of available samples.

core  

Stress‐Programmed Immune Niches Fuel TNFR2+ Treg Activation and Drive Neoadjuvant Chemotherapy Resistance in Breast Cancer

open access: yesAdvanced Science
The tumor microenvironment (TME) harbors diverse immune cell states that shape therapeutic outcomes in breast cancer. Here, we identify a conserved stress‐programmed cellular module as a key responder to neoadjuvant therapies in breast cancer ...
Zhibo Shao   +18 more
doaj   +1 more source

Time to maximal response of trastuzumab deruxtecan in patients with HER2-Positive metastatic breast cancer: A multicenter retrospective study (TRACE)

open access: yesBreast
Background: Trastuzumab deruxtecan (T-DXd) has demonstrated transformative efficacy in HER2-positive metastatic breast cancer (MBC), and induction–maintenance strategies with T-DXd are under investigation to optimize the treatments.
Yukinori Ozaki   +20 more
doaj   +1 more source

Pathological response and metabolites’ prognostic role in HER2-positive breast cancer treated with neoadjuvant pyrotinib, trastuzumab, nab-paclitaxel, and carboplatin: a single-arm phase II trial

open access: yesBreast Cancer Research
Background The trial aimed to evaluate the efficacy and safety of pyrotinib in combination with trastuzumab, nab-paclitaxel, and carboplatin (TCbHPy) in the neoadjuvant setting (ChiCTR2100043523), as well as the role of metabolites in predicting the ...
Mei Liu   +10 more
doaj   +1 more source

Cancer Trends: Breast cancer 1994-2016

open access: yes, 2019
There were 62,052 cases of newly diagnosed invasive or in situ breast tumours registered in Ireland by the National Cancer Registry for the period 1994–2016, of which 56,366 were invasive (ICD10: C50) and 5,686 were carcinoma in situ (ICD10: D05 ...
National Cancer Registry Ireland (NCRI)
core  

BCTB Invasive Breast Cancer Samples and Images

open access: yes
This BCTB subcollection contains breast tissue and blood samples, and associated images, where a diagnosis of invasive cancer has been determined by a ...

core  

Chidamide combined with fulvestrant in the treatment of HR-positive, HER2-negative advanced breast cancer after failure of previous endocrine therapy: a single-arm, single-center, phase 2 study

open access: yesBreast Cancer Research
Background Chidamide is an oral subtype-selective histone deacetylase inhibitor that has been used as an anti-cancer agent. This study evaluated the efficacy and safety of chidamide plus fulvestrant in the treatment of HR-positive and HER2-negative ...
La Zou   +8 more
doaj   +1 more source

Docetaxel rechallenge in HER2-negative metastatic breast cancer: a real-world study of previously discontinued patients for non-progression reasons

open access: yesJournal of Cancer Research and Clinical Oncology
Purpose This study aimed to evaluate the efficacy and safety of docetaxel rechallenge in HER2-negative metastatic breast cancer (MBC) patients who discontinued docetaxel for reasons other than disease progression.
Hui-Ai Zeng   +7 more
doaj   +1 more source

Home - About - Disclaimer - Privacy